Morten Ingvar Lossius

Morten Ingvar Lossius

Auto-generated profile, based on publicly available information

Morten Ingvar Lossius

Division of Clinical Neuroscience National Center for Epilepsy, full member of European Reference Network EpiCARE, Oslo University Hospital Oslo Norway

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in Epilepsia
Verified
Journal Article
Open access
PDF file
KKKonstantin H. Kostov
Konstantin H. Kostov
HKHrisimir Kostov
Hrisimir Kostov
PLPål Gunnar Larsson
Pål Gunnar Larsson
OHOliver Henning
Oliver Henning
CEChristian Alexander Cornelius Eckmann
Christian Alexander Cornelius Eckmann
JPJukka Peltola
Jukka Peltola
Objective: This study was undertaken to evaluate the efficacy of vagus nerve stimulation (VNS) over time, and to determine which patient groups derive the most benefit.Methods: Long‐term outcomes are reported in 436 epilepsy patients from a VNS quality registry (52.8% adults, 47.2% children), with a median follow‐up of 75 months. Patients were stratified according to evolution of response into constant responders, fluctuating responders, and nonresponders. The effect was evaluated at 6, 12, 24, 36, and 60 months. Multivariate regression analysis was used to identify predictors of response.Results: The cumulative probability of ≥50% seizure reduction was 60%; however, 15% of patients showed a fluctuating course. Of those becoming responders, 89.5% (230/257) did so within 2 years. A steady increase in effect was observed among constant responders, with 48.7% (19/39) of those becoming seizure‐free and 29.3% (39/133) with ≥75% seizure reduction achieving these effects within 2–5 years. Some effect (25%–<50%) at 6 months was a positive predictor of becoming a responder (odds ratio [OR] = 10.18, p < .0001) and having ≥75% reduction at 2 years (OR = 3.34, p = .03). Patients without intellectual disability had ORs of 3.34 and 3.11 of having ≥75% reduction at 2 and 5 years, respectively, and an OR of 6.22 of being seizure‐free at last observation. Patients with unchanged antiseizure medication over the observation period showed better responder rates at 2 (63.0% vs. 43.1%, p = .002) and 5 years (63.4% vs. 46.3%, p = .031) than patients whose antiseizure medication was modified. Responder rates were higher for posttraumatic (70.6%, p = .048) and poststroke epilepsies (75.0%, p = .05) than other etiologies (46.5%).Significance: Our data indicate that the effect of VNS increases over time and that there are important clinical decision points at 6 and 24 months for evaluating and adjusting the treatment. There should be better selection of candidates, as certain patient groups and epilepsy etiologies respond more favorably.

11 January 2025 in Epilepsia
Verified
Journal Article
Open access
TVTruls Vikin
Truls Vikin
MLMorten I. Lossius
Morten I. Lossius
RBRagnhild E. Brandlistuen
Ragnhild E. Brandlistuen
RCRichard F. Chin
Richard F. Chin
KAKari M. Aaberg
Kari M. Aaberg
Objective: This study was undertaken to describe incidence and distribution of seizures, etiologies, and epilepsy syndromes in the general child and youth population, using the current International League Against Epilepsy (ILAE) classifications. Methods: The study platform is the Norwegian Mother, Father, and Child Cohort Study (MoBa). Epilepsy cases were identified through registry linkages facilitated by Norway's universal health care system and mandatory reporting to the Norwegian Patient Registry. A standardized protocol guided medical record review, leading to validation of diagnoses and classification of seizures, epilepsy types, syndromes, and etiologies based on the latest ILAE criteria. Results: MoBa included 111 365 participants aged 12–21 years by the end of follow‐up on December 31, 2020. We identified 1053 children and youth with epilepsy (CYE). A defined epilepsy syndrome and/or identified etiology was found in 76% of CYE in this population‐based study. Seizure types exhibited variation by age at onset. Focal epilepsies were predominant, occurring in 61% of CYE, whereas generalized epilepsies were identified in 24% of CYE. Standard clinical assessment identified etiology in 30% of CYE and in 55% with onset age < 2 years. Structural and identified genetic etiologies constituted 21% and 10%, respectively. Including presumed genetic and rare etiologies, 53% exhibited known etiology. A defined ILAE epilepsy syndrome was found in 53% of CYE. The cumulative incidence per 1000 children of the following ILAE epilepsy syndrome groups were as follows: self‐limited epilepsies, 2.25; idiopathic generalized epilepsies, 1.75; and developmental and/or epileptic encephalopathies, 2.62. Significance: Using the new ILAE classifications, this population‐based childhood study provides incidences of seizures, epilepsies, and epilepsy syndromes. Half of epilepsy cases are classified as an ILAE epilepsy syndrome with its prognostic and therapeutic implications, but a substantial proportion of cases still have unknown etiology.

26 October 2006 in Epilepsia
Verified
Journal Article
Closed access
PDF file
EHErik Hessen
Erik Hessen
MLMorten I. Lossius
Morten I. Lossius
IRIvar Reinvang
Ivar Reinvang
LGLeif Gjerstad
Leif Gjerstad

6 February 2024 in Epilepsia Open
Verified
Journal Article
Open access
KKKonstantin H. Kostov
Konstantin H. Kostov
HKHrisimir Kostov
Hrisimir Kostov
PLPål Gunnar Larsson
Pål Gunnar Larsson
OHOliver Henning
Oliver Henning
KAKari Modalsli Aaberg
Kari Modalsli Aaberg
MLMorten Ingvar Lossius
Morten Ingvar Lossius
Objective: Evaluate the long‐term efficacy of vagus nerve stimulation (VNS) in patients with developmental and epileptic encephalopathies (DEE) compared with epilepsy patients without intellectual disability (ID).Methods: Long‐term outcomes from a Norwegian VNS quality registry are reported in 105 patients with DEEs (Lennox–Gastaut syndrome [LGS] n = 62; Dravet n = 16; Rett n = 9; other syndromes n = 18) were compared with 212 epilepsy patients without ID, with median follow‐up of 88 and 72 months, respectively. Total seizure reduction was evaluated at 6, 12, 24, 36, and 60 months. Effect on different seizure types was evaluated at baseline and last observation carried forward (LOCF).Results: Median monthly seizure frequency at LOCF was reduced by 42.2% (p < 0.001) in patients with DEE and by 55.8% (p < 0.001) in patients without ID. In DEE patients, ≥50% seizure reduction at 6 and 24 months were 17.1% and 37.1%, respectively, and 33.5% and 48.6% for patients without ID. Seizure reduction ≥75% at 60 months occurred in 14.3% of DEE patients and 23.1% of patients without ID. Highest median reduction was for atonic seizures, most notably 64.6% for LGS patients. A better effect was seen at 2 years among DEE patients with unchanged medication compared with those with changed medication (54.5% vs. 35.6% responders, p = 0.078). More DEE patients were reported to have greater improvement in ictal or postictal severity (43.8% vs. 28.3%, p = 0.006) and alertness (62.9% vs. 31.6%, p < 0.001) than patients without ID. For both groups, use of the magnet reduced seizure severity. Hoarseness was the most common adverse effect in both groups. In addition, DEE patients were frequently reported to have sleep disturbance, general discomfort, or abdominal problems.Significance: Our data indicate that VNS is very effective for atonic seizures. Patients without ID had best overall seizure reduction, however, patients with DEE had higher retention rates probably due to other positive effects.Plain Language Summary: DEE refers to a group of patients with severe epilepsy and intellectual disability. Many of these patients have restricted lifestyles with frequent seizures. VNS is a treatment option for patients who do not respond well to medicines, either because of insufficient effect or serious adverse effects. Our study shows that VNS is well tolerated in this patient group and leads to a reduction in all seizure types, most notably for seizures leading to fall. Many patients experience other positive effects like shorter and milder seizures, as well as improvement in alertness.

1 July 2025 in Brain Stimulation
Verified
Journal Article
Open access
KKKonstantin Hrisimirov Kostov
Konstantin Hrisimirov Kostov
HKHrisimir Kostov
Hrisimir Kostov
PLPål Gunnar Larsson
Pål Gunnar Larsson
OHOliver Henning
Oliver Henning
AEArild Egge
Arild Egge
JPJukka Peltola
Jukka Peltola
Despite widespread use of vagus nerve stimulation (VNS), evidence regarding optimal stimulation titration and dosing remains limited. Significant inter-practice variability and deviation from guidelines, results in sub-optimal dosing. Identify optimal stimulation parameters and establish target dosing for VNS therapy in epilepsy. We linked long-term outcomes with dosing parameters in 415 patients from a VNS registry (median follow-up=79.0 months). A generalized linear mixed model (GLMM) assessed relationships between stimulation parameters (Output Current (OC), Frequency, Pulse Width (PW), Duty cycle (DC)) and very good clinical response (≥75% seizure frequency reduction from baseline). Output current was the strongest predictor of seizure reduction (p=0.001). Increasing OC by 1mA more than doubled the probability of ≥75% seizure reduction, peaking at 2.70mA. Greatest likelihood of ≥50% seizure reduction was at 2.1mA. Post-hoc analysis supported GLMM findings, showing significantly more patients (46.3%) receiving >2.0mA OC achieved ≥75% seizure reduction compared with 30.7% (p=0.01) among patients using lower OC. Although changes in DC were not significantly associated with seizure reduction, post-hoc analysis suggested benefits from other duty cycles. Standard 250μs PW and 20Hz frequency were associated with best effect. Longer follow-up improved seizure control (p<0.001); intellectual disability negatively impacted response (p=0.005). Seizure-free patients had significantly lower total charge (122.4 vs. 250.1mC, p=0.014) than patients with persistent seizures. Output current should be the primary focus when titrating VNS patients to optimal dose. We suggest a target range of 1.5 - 2.25mA with 250μs PW and 20Hz frequency. Higher OC should be attempted if tolerated.

9 October 2025 in Epilepsia
Verified
Journal Article
Open access
LWLine Kønig Wilms
Line Kønig Wilms
MLMorten I. Lossius
Morten I. Lossius
KAKaapo Annala
Kaapo Annala
JAJonas Abdel‐Khalik
Jonas Abdel‐Khalik
LFLena Fanter
Lena Fanter
JPJukka Peltola
Jukka Peltola
Objective: This study aimed to assess the performance of the Nelli seizure monitoring system in detecting and classifying seizures during sleep or while at rest in bed in patients with Lennox–Gastaut syndrome (LGS) and Dravet syndrome (DS). Methods: We conducted a non‐interventional, single‐center feasibility study from August 2023 to March 2024, involving 20 patients aged ≥2 years diagnosed with DS or LGS. Participants used Nelli for home‐based seizure monitoring during sleep or while at rest in bed for 4 weeks. Seizures were detected and classified by Nelli, and results were compared to epileptologist reviews and seizure diaries. Results: Of 20 enrolled patients, 14 (70%) who experienced seizures at rest were included in the analyses. Among them, Nelli detected 368 seizures, with an accuracy of 97.8%, as confirmed by independent reviewers. Eight seizures (2.2%) detected by Nelli were false positives, identified as part of a single seizure episode. Of the 14 patients, only 35.7% reported experiencing seizures in their diaries, and only 26.1% of the seizures were documented. Seizure durations ranged from 6 to 396 s, with considerable variation. Nelli demonstrated high accuracy in seizure classification (Gwet agreement coefficient [AC1] = .81–1.00) in nine of 14 cases. However, in three of 14 patients, moderate accuracy (AC1 = .41–.60) was observed due to challenges in classifying seizures in patients with high seizure frequency or suboptimal device positioning. The average classification accuracy of Nelli for tonic–clonic seizures was .99 (150/152 seizures), tonic seizures .55 (102/186), clonic seizures 1.00 (3/3), focal motor seizures .89 (16/18), and myoclonic seizures 1.00 (1/1). Significance: Nelli demonstrated high sensitivity and classification accuracy for detecting and categorizing seizures in bed in patients with DS and LGS, outperforming seizure diaries and providing a reliable tool for seizure monitoring in home settings.